Diakonos Oncology Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Series A
  • (Upcoming)

  • Investors
  • 4

Diakonos Oncology General Information

Description

Developer of a clinical-stage immunotherapy platform intended to focus on treating aggressive cancers. The company utilizes a proprietary double-loaded, patient-derived dendritic cell therapeutic technology to address unmet medical needs in late-stage oncology, enabling cancer treatment through targeted and personalized immune system activation.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Houston, TX 77058
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Houston, TX 77058
  • United States

Diakonos Oncology Timeline

2023202420252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Diakonos Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) Upcoming Clinical Trials - Phase 2
2. Early Stage VC 30-May-2025 Completed Clinical Trials - Phase 2
1. Seed Round 26-Aug-2024 $11.4M $11.4M Completed Clinical Trials - Phase 2
To view Diakonos Oncology’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Diakonos Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Diakonos Oncology Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
BCM Ventures Venture Capital Minority
Buttonwood Group Advisors Asset Manager
The Brain Tumor Investment Fund Not-For-Profit Venture Capital
RESTEM (Biotechnology) Corporation Minority
To view Diakonos Oncology’s complete investors history, request access »

Diakonos Oncology FAQs

  • When was Diakonos Oncology founded?

    Diakonos Oncology was founded in 2022.

  • Where is Diakonos Oncology headquartered?

    Diakonos Oncology is headquartered in Houston, TX.

  • What is the size of Diakonos Oncology?

    Diakonos Oncology has 14 total employees.

  • What industry is Diakonos Oncology in?

    Diakonos Oncology’s primary industry is Drug Discovery.

  • Is Diakonos Oncology a private or public company?

    Diakonos Oncology is a Private company.

  • What is Diakonos Oncology’s current revenue?

    The current revenue for Diakonos Oncology is .

  • How much funding has Diakonos Oncology raised over time?

    Diakonos Oncology has raised $31.4M.

  • Who are Diakonos Oncology’s investors?

    BCM Ventures, Buttonwood Group Advisors, The Brain Tumor Investment Fund, and RESTEM (Biotechnology) have invested in Diakonos Oncology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process